Swiss drugmaker Roche on 17 September 2026 reported positive late‑stage clinical trial results for Lunsumio, administered in combination with another agent, in patients with follicular lymphoma. The company said the outcome represents a key research milestone and indicated that Lunsumio is expected to be a driver of future growth for Roche.
Roche provided limited detail in the announcement, stating only that the late‑phase study showed positive outcomes for the combination regimen in treating follicular lymphoma. No additional efficacy or safety data were disclosed in the note.
Follicular lymphoma is a common indolent form of non‑Hodgkin lymphoma; effective new combination therapies can change treatment options and commercial prospects. Roche’s designation of Lunsumio as a growth product will be followed as further data and regulatory steps are reported. #Roche #Lunsumio #follicularlymphoma #FiatNews
Fiat News 💵📰
npub1fn…eh4rg
2026-09-17 09:35:02 UTC
Author Public Key
npub1fnewsheweaahslyw3luvshwrj3q7e7qhxzxjww37df222a9j2shszeh4rgPublished at
2026-09-17 09:35:02 UTCEvent JSON
{
"id": "f53371ff3c4e3c3c9ef42b7e9277175a2d82c777b9768c742bc4485b7385e457",
"pubkey": "4cf2e85f2ecf7b787c8e8ff8c85dc39441ecf817308d273a3e6a54a574b2542f",
"created_at": 1789637702,
"kind": 1,
"tags": [
[
"t",
"Roche"
],
[
"t",
"roche"
],
[
"t",
"Lunsumio"
],
[
"t",
"lunsumio"
],
[
"t",
"follicularlymphoma"
],
[
"t",
"FiatNews"
],
[
"t",
"fiatnews"
]
],
"content": "Swiss drugmaker Roche on 17 September 2026 reported positive late‑stage clinical trial results for Lunsumio, administered in combination with another agent, in patients with follicular lymphoma. The company said the outcome represents a key research milestone and indicated that Lunsumio is expected to be a driver of future growth for Roche. \n\nRoche provided limited detail in the announcement, stating only that the late‑phase study showed positive outcomes for the combination regimen in treating follicular lymphoma. No additional efficacy or safety data were disclosed in the note.\n\nFollicular lymphoma is a common indolent form of non‑Hodgkin lymphoma; effective new combination therapies can change treatment options and commercial prospects. Roche’s designation of Lunsumio as a growth product will be followed as further data and regulatory steps are reported. #Roche #Lunsumio #follicularlymphoma #FiatNews",
"sig": "90b188cffd95f8e0267450879382e9308b942c64172aca924ae2f80bd0bd4e6b099270d6aabc994953b2408ed2d2e44bc1b6c527dfd2ed699ce9f6b11b90f195"
}